Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease
| Autor: | Lawrence M. Title, Jean Buithieu, Paul Poirier, Ann Walling, Jacques Genest, Eva Lonn, Francois Charbonneau, Sammy Chan, Jean-Francois Dorval, Thao Huynh, Ghyslain Boudreau, Jean Jobin, Thang Tran, Stuart Hutchison, Todd J. Anderson |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Canada medicine.medical_specialty Atorvastatin Blood Pressure Coronary Artery Disease Drug Administration Schedule chemistry.chemical_compound Internal medicine medicine Humans AMLODIPINE/ATORVASTATIN Pyrroles In patient Amlodipine Antihypertensive Agents Triglycerides business.industry Cholesterol Cholesterol HDL Cholesterol LDL Middle Aged Coronary heart disease Treatment Outcome Blood pressure Endocrinology chemistry Heptanoic Acids Drug Therapy Combination Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug Lipoprotein |
| Zdroj: | The American Journal of Cardiology. 95:249-253 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2004.09.012 |
| Popis: | The effects of combined atorvastatin and amlodipine on blood pressure (BP) and low-density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with documented coronary heart disease treated for 1 year. BP at baseline was 128 +/- 15/79 +/- 9 mm Hg and was controlled by the treating physician; no calcium channel blockers were allowed. Baseline means for plasma cholesterol were 6.4 +/- 1.1 mmol/L (147 +/- 39 mg/dl), triglycerides 2.0 +/- 0.9 mmol/L (177 +/- 88 mg/dl), LDL cholesterol 4.4 +/- 1.0 mmol/L (170 +/- 39 mg/dl), and high-density lipoprotein cholesterol 1.2 +/- 0.3 mmol/L (46 +/- 12 mg/dl). Patients were all given atorvastatin 10 mg, then increased to 80 mg if the LDL cholesterol was2.5 mmol/L (100 mg/dl). At 3 months, patients were randomized to amlodipine 10 mg or placebo. Plasma LDL cholesterol was decreased by 50%, and the LDL cholesterol target of2.5 mmol/L was achieved in 81% of the patients. BP targets were achieved in 69% of the atorvastatin + placebo group, versus 96% in the atorvastatin + amlodipine group (p = 0.0002). With use of combination atorvastatin + amlodipine at doses ranging from 10 to 80 mg and 5 to 10 mg, respectively, recommended therapeutic goals were reached in most select subjects with coronary artery disease who were concomitantly receiving aspirin and antihypertensive therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect